CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...